Skip to content
MedsAcross

Medicine

Plerixafor 24 mg/1.2 mL injection

Plerixafor · Subcutaneous
Available on requestPrescription onlyUS FDAGeneric name

Plerixafor 24 mg/1.2 mL injection is a generic prescription medicine for subcutaneous use, made by 11 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).

Key facts

Active ingredient (INN)
Plerixafor
Brand
Sold under the generic name
Strength
24 mg/1.2 mL
Dosage form
Injection
Route
Subcutaneous
Packs
1 vial of 1.2 mL and 9 more
Manufacturers
Zydus LifesciencesIndiaCamber PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaEugiaIndiaGland PharmaIndiaNovadoz PharmaceuticalsIndiaAmneal PharmaceuticalsBryant Ranch PrepackFresenius KabiMeitheal Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L03AX16 Plerixafor
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
22 June 2023
Identifiers
RxCUI 828700DailyMed set ID bb8e1167-8378-4e73-9bcb-d69093ec829b, 58c9fa02-3701-d411-f946-790a62ddc064, 43df348a-d7f2-4f14-8131-c916679a98eb +9NDC 31722-373, 43598-308, 70771-1776 +9Application ANDA217560, ANDA205182, ANDA208980 +6

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use70710-1208-1Zydus LifesciencesIndia28 July 2023
1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use70771-1776-1Zydus LifesciencesIndia28 July 2023
1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use31722-373-31Camber PharmaceuticalsIndia16 June 2025
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose43598-308-23Dr. Reddy's LaboratoriesIndia6 November 2023
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose55150-356-01EugiaIndia24 July 2023
1 vial in 1 carton / 1.2 mL in 1 vial68083-155-01Gland PharmaIndia3 May 2024
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose72205-249-01Novadoz PharmaceuticalsIndia25 July 2023
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose70121-1694-2Amneal Pharmaceuticals25 July 2023
1 vial, single-use in 1 carton / 1.2 mL in 1 vial, single-use65219-284-12Fresenius Kabi22 June 2023
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose71288-155-01Meitheal Pharmaceuticals24 July 2023
1 vial in 1 carton / 1.2 mL in 1 vial25021-416-01Sagent Pharmaceuticals1 August 2024
1 vial, single-dose in 1 carton / 1.2 mL in 1 vial, single-dose72162-2642-2Bryant Ranch Prepack6 May 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 15 December 2008Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Plerixafor 24 mg/1.2 mL injection.

Compare 1

Clinical summary

Plerixafor is a hematopoietic stem cell mobilizer. It is available as injection for subcutaneous use. MedsAcross supplies Plerixafor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Plerixafor

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Plerixafor 24 mg/1.2 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.